LONDON--(BUSINESS WIRE)--Three global pharmaceutical companies (AstraZeneca, GlaxoSmithKline, Johnson & Johnson Innovation) and the technology transfer offices of three world-leading universities (Imperial College London, University College London and the University of Cambridge) have joined forces with a combined £40 million to create the Apollo Therapeutics Fund (‘Apollo’). This pioneering new joint venture will support the translation of ground-breaking academic science from within these universities into innovative new medicines for a broad range of diseases.
